CARs on a highway with roadblocks

OncoImmunology

Volumn 6, Issue 12, 2017, Pages

  Galluzzi, Lorenzo ^a,b   Martin, Peter ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

acute lymphoblastic leukemia; chimeric antigen receptor; gene therapy; immunotherapy; KYMRIAH ; tisagenlecleucel

Indexed keywords

PROTEIN P53; TISAGENLECLEUCEL T; TOCILIZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; CAR; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; IMMUNOTHERAPY; TRAFFIC;

EID: 85032707496     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1388486     Document Type: Editorial

References (21)

1. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724–40. doi:10.1016/j.cell.2017.01.016. PMID:28187291
2. CAR T-cells: an exciting frontier in cancer therapy. Lancet. 2017;390:1006. doi:10.1016/S0140-6736(17)32395-4.
3. Pagel JM, West HJ. Chimeric Antigen Receptor (CAR) T-Cell Therapy. JAMA Oncol. 2017. doi:10.1001/jamaoncol.2017.2989. PMID:28880983
4. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–76. doi:10.1038/nrclinonc.2013.46. PMID:23546520
5. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370–83. doi:10.1038/nrclinonc.2016.36. PMID:27000958
6. van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499–509. doi:10.1038/nrd4597. PMID:26129802
7. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5:e1253656. doi:10.1080/2162402X.2016.1253656. PMID:28180032
8. Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e1008814. doi:10.1080/2162402X.2015.1008814. PMID:26137403
9. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566–81. doi:10.1038/nrc.2016.97. PMID:27550819
10. Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ. CAR-T cells are serial killers. Oncoimmunology. 2015;4:e1053684. doi:10.1080/2162402X.2015.1053684. PMID:26587330
11. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28. doi:10.1016/S0140-6736(14)61403-3. PMID:25319501
12. Aranda F, Buque A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology. 2015;4:e1046673. doi:10.1080/2162402X.2015.1046673. PMID:26451319
13. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18:666–8. doi:10.1038/mt.2010.31. PMID:20357779
14. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51. doi:10.1038/mt.2010.24. PMID:20179677
15. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017. doi:10.1038/nrclinonc.2017.148. PMID:28925994
16. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30. doi:10.1182/blood-2016-04-703751. PMID:27207799
17. Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther. 2009;2:115–22. PMID:19920899
18. Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5:e1117740. doi:10.1080/2162402X.2015.1117740. PMID:27057469
19. Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol. 2012;13:1852–7. doi:10.2174/138920112800958760. PMID:21740357
20. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120:1165–74. doi:10.1182/blood-2012-05-378943. PMID:22730540
21. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62:61–73. doi:10.1016/j.pcl.2014.09.006. PMID:25435112